Agios Pharmaceuticals vs Amylyx Pharmaceuticals
Agios Pharmaceuticals' revenue grew 48.0% in its latest year, and Amylyx Pharmaceuticals' fell 100.0%. Free cash flow was −$377 million at Agios Pharmaceuticals and −$123 million at Amylyx Pharmaceuticals.
Side by side
| Agios Pharmaceuticals | Amylyx Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $54M | $0M |
| Revenue growth | 48.0% | −100.0% |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | 88.3% | — |
| Operating margin | −873.9% | — |
| Net margin | −764.0% | — |
| Free cash flow | −$377M | −$123M |
| Free cash flow margin | −698.3% | — |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 0.1% | 38.8% |
| Last close | $31.59 | $30.29 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $4.3 million | bought $152,183, sold $16.4 million |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Agios PharmaceuticalsAmylyx Pharmaceuticals
Operating margin
Percent of revenue
Agios PharmaceuticalsAmylyx Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Agios PharmaceuticalsAmylyx Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Agios Pharmaceuticals and Amylyx Pharmaceuticals pages.